homemarket NewsLaurus Labs shares hit 52 week high, surge over 14% this year, so far

Laurus Labs shares hit 52-week high, surge over 14% this year, so far

Laurus Labs Share Price | The drug maker owns more than 40% stake in Immunoadoptive Cell Therapy (ImmunoACT) Private Ltd, that developed India’s first Chimeric antigen receptor (CAR) T-cell therapy, which plays a major role in cancer treatment.

By CNBCTV18.com Dec 26, 2023 4:07:09 PM IST (Updated)

2 Min Read
Laurus Labs shares jumped more than 4% to hit a fresh 52-week high of ₹435 per piece on Tuesday, extending gains for the third straight day, amid a positive outlook for its associate firm ImmunoACT.
The stock has gained 14.51% this year, so far. It has already made a healthy recovery of 54.8% from its 52-week low of ₹279.6 per piece on the BSE.
The drug maker owns more than 40% stake in Immunoadoptive Cell Therapy (ImmunoACT) Private Ltd, that developed India’s first Chimeric antigen receptor (CAR) T-cell therapy, which plays a major role in cancer treatment.